Premium
A simultaneous oral and intramuscular prime/sublingual boost with a DNA/Modified Vaccinia Ankara viral vector‐based vaccine induces simian immunodeficiency virus‐specific systemic and mucosal immune responses in juvenile rhesus macaques
Author(s) -
Curtis Alan D.,
Jensen Kara,
Van Rompay Koen K. A.,
Amara Rama R.,
Kozlowski Pamela A.,
De Paris Kristina
Publication year - 2018
Publication title -
journal of medical primatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 42
eISSN - 1600-0684
pISSN - 0047-2565
DOI - 10.1111/jmp.12372
Subject(s) - simian immunodeficiency virus , modified vaccinia ankara , virology , immune system , immunology , vaccinia , virus , antibody , biology , viral load , medicine , recombinant dna , gene , biochemistry
Background A pediatric vaccine to prevent breast milk transmission of human immunodeficiency virus (HIV) may generate greater immune responses at viral entry sites if given by an oral route. Methods We compared immune responses induced in juvenile macaques by prime/boosting with simian immunodeficiency virus (SIV)‐expressing DNA/modified vaccinia Ankara virus (MVA) by the intramuscular route (IM), the oral (O)/tonsillar routes (T), the O/sublingual (SL) routes, and O+IM/SL routes. Results O/T or O/SL immunization generated SIV‐specific T cells in mucosal tissues but failed to induce SIV‐specific IgA in saliva or stool or IgG in plasma. IM/IM or O+IM/SL generated humoral and cellular responses to SIV. IM/IM generated greater frequencies of T FH in spleen, but O+IM/SL animals had higher avidity plasma IgG and more often demonstrated mucosal IgA responses. Conclusion These results suggest that codelivery of HIV DNA/MVA vaccines by the oral and IM routes might be optimal for generating both systemic and mucosal antibodies.